Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Cassava Sciences Stock Quote

Cassava Sciences (NASDAQ: SAVA)

Price as of March 4, 2024, 4:00 p.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cassava Sciences Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
SAVA -9.45% +1,816.67% +80.40% -80%
S&P +29.03% +83.23% +12.86% +240%

Cassava Sciences Company Info

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

News & Analysis

The Fool has written over 100 articles on Cassava Sciences.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.